Browse IL34

Summary
SymbolIL34
Nameinterleukin 34
Aliases MGC34647; IL-34; C16orf77; chromosome 16 open reading frame 77; Interleukin-34
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF15036 Interleukin 34
Function

Cytokine that promotes the proliferation, survival and differentiation of monocytes and macrophages. Promotes the release of proinflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast proliferation and differentiation, and in the regulation of bone resorption. Signaling via CSF1R and its downstream effectors stimulates phosphorylation of MAPK1/ERK2 AND MAPK3/ERK1.

> Gene Ontology
 
Biological Process GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002763 positive regulation of myeloid leukocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030224 monocyte differentiation
GO:0030225 macrophage differentiation
GO:0045637 regulation of myeloid cell differentiation
GO:0045639 positive regulation of myeloid cell differentiation
GO:0045649 regulation of macrophage differentiation
GO:0045651 positive regulation of macrophage differentiation
GO:0045655 regulation of monocyte differentiation
GO:0045657 positive regulation of monocyte differentiation
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903131 mononuclear cell differentiation
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
Molecular Function GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005157 macrophage colony-stimulating factor receptor binding
GO:0008083 growth factor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-449147: Signaling by Interleukins
Summary
SymbolIL34
Nameinterleukin 34
Aliases MGC34647; IL-34; C16orf77; chromosome 16 open reading frame 77; Interleukin-34
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IL34 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IL34 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27550451Lung CarcinomaInhibit immunity (T cell function); immunotherapy targetIn particular, we found that IL34 modulated the functions of tumor-associated macrophages to enhance local immunosuppression and to promote the survival of chemoresistant cancer cells by activating AKT signaling. Targeting IL34 in chemoresistant tumors resulted in a remarkable inhibition of tumor growth when accompanied with chemotherapy.
Summary
SymbolIL34
Nameinterleukin 34
Aliases MGC34647; IL-34; C16orf77; chromosome 16 open reading frame 77; Interleukin-34
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IL34 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIL34
Nameinterleukin 34
Aliases MGC34647; IL-34; C16orf77; chromosome 16 open reading frame 77; Interleukin-34
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IL34 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0170.972
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3850.692
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2640.7
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4420.352
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7670.493
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0350.978
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3690.478
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5210.501
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0720.934
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8760.475
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7830.656
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1370.452
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IL34 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIL34
Nameinterleukin 34
Aliases MGC34647; IL-34; C16orf77; chromosome 16 open reading frame 77; Interleukin-34
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL34. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIL34
Nameinterleukin 34
Aliases MGC34647; IL-34; C16orf77; chromosome 16 open reading frame 77; Interleukin-34
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL34. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL34.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIL34
Nameinterleukin 34
Aliases MGC34647; IL-34; C16orf77; chromosome 16 open reading frame 77; Interleukin-34
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL34. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIL34
Nameinterleukin 34
Aliases MGC34647; IL-34; C16orf77; chromosome 16 open reading frame 77; Interleukin-34
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IL34 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIL34
Nameinterleukin 34
Aliases MGC34647; IL-34; C16orf77; chromosome 16 open reading frame 77; Interleukin-34
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IL34 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIL34
Nameinterleukin 34
Aliases MGC34647; IL-34; C16orf77; chromosome 16 open reading frame 77; Interleukin-34
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IL34 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.